| Document |
Document Title |
|
WO/2021/236971A1 |
A highly active and selective solid catalyst comprising stable single-atom iridium (Ir) anchored in a zeolite, e.g., ZSM-5, for upcycling of plastics, such as high-density polyethylene, to yield valuable lower molecular weight hydrocarbo...
|
|
WO/2021/236771A1 |
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-Ll or the PD-1/PD-Ll interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
|
|
WO/2021/228000A1 |
The preparation of an aromatic heterocyclic derivative as an immunomodulator and the use thereof. Specifically, provided is a compound as represented by formula I below, or an optical isomer, a hydrate, a solvate, or a pharmaceutically a...
|
|
WO/2021/223718A1 |
The present invention relates to the fields of pharmacochemistry and pharmacotherapy, and in particular relates to compounds of general formula I as 3CL protease inhibitors of SARS-CoV-2. At the same time, the compounds have significant ...
|
|
WO/2021/226276A2 |
Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a ph...
|
|
WO/2021/223066A1 |
A raw material filtering device for pyromellitic dianhydride production, comprising a box body (1), a first support plate (21), a second support plate (23), a carrying frame (31), a filter screen (3), and an opening (32); wherein the fir...
|
|
WO/2021/222858A1 |
Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the tre...
|
|
WO/2021/218992A1 |
Disclosed are a substituted pyrrolidine compound and the use thereof in medicine. In particular, disclosed are a substituted pyrrolidine compound or a stereoisomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, a phar...
|
|
WO/2021/217579A1 |
Disclosed is a method for preparing a brivaracetam intermediate shown in formula B-R, comprising: reacting a compound shown in formula B-P and a resolving agent to prepare a compound shown in formula B-Q; and converting the compound show...
|
|
WO/2021/219661A1 |
The present invention relates to compounds showing pharmacological activity towards the subunit α2δof voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels. More particularly, the in...
|
|
WO/2021/214727A1 |
Cancer stem cells are responsible for tumor recurrence, distant metastasis and drug-resistance, in the vast majority of cancer patients. There exists an urgent need to identify new mitochondrial inhibitor drugs that can target and eradic...
|
|
WO/2021/217053A1 |
Provided herein are methods of treating an acute respiratory syndrome, non-cardiogenic pulmonary edema, viral infections, coronavirus disease 2019 (COVID-19), and/or systemic inflammatory response syndrome (SIRS) in the subject in need t...
|
|
WO/2021/214278A2 |
The present invention relates to regioselective chemical and electrochemical processes for the preparation of an oxidized heterocyclic alpha-amino amide compounds. By applying specific catalysts or catalyst systems during chemical oxidat...
|
|
WO/2021/214283A1 |
The present invention relates to a novel biocatalytic process for the stereoselective preparation of alpha amino amide compounds catalyzed by NHase enzymes. A further aspect of the invention relates to novel NHase enzymes as well as furt...
|
|
WO/2021/216660A1 |
The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for dismption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
|
|
WO/2021/211913A1 |
Novel direct thrombin inhibitors are provided herein, along with methods for their use as anticoagulants. The direct thrombin inhibitors described herein are useful in treating and/or preventing thromboembolism and bleeding or clotting d...
|
|
WO/2021/209490A1 |
The present disclosure relates to fungicidal active compounds, more specifically to cyclaminephenylaminoquinolines of formula (I), intermediates for their preparation and use thereof as fungicidal active compound, particularly in the for...
|
|
WO/2021/210997A1 |
Water-soluble analogs of compounds intended for the treatment of neurological diseases, epilepsy, neuropathic pain and migraine, and psychiatric disorders, including anxiety and depression, especially suitable for the preparation of oral...
|
|
WO/2021/206876A1 |
Compounds of Formula (I) and methods of inhibiting the replication of viruses in a biological sample or patient, of reducing the amount of viruses in a biological sample or patient, and of treating a virus infection in a patient, compris...
|
|
WO/2021/204175A1 |
Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid...
|
|
WO/2021/202460A1 |
Compounds exhibiting antiviral activity and/or inhibition of viral replication against viruses, particularly those belonging to the picornavirus-like supercluster, including coronavirus having a formula: (I) where X comprises a cyclic mo...
|
|
WO/2021/202781A1 |
Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, n, R1, R2, R6, R7, R8, R9, R10, X3, X4 and X5 are defined in the specification. This disclosure also relates to materials and methods for pre...
|
|
WO/2021/197486A1 |
A novel spiro compound and an application thereof in a drug, in particular, use thereof as a drug for treating and/or preventing hepatitis B. Specifically, the present invention relates to a compound represented by formula (I) or a stere...
|
|
WO/2021/202977A1 |
Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the comp...
|
|
WO/2021/201126A1 |
An amide compound represented by formula (I-1) or a salt thereof, a pharmaceutical composition that comprises the amide compound or a salt thereof, and a histone deacetylase inhibitor. In the formula: R1 to R4 independently represent a h...
|
|
WO/2021/197303A1 |
Provided in the present invention are a method for preparing a long-chain fatty diacid monobenzyl ester. The method comprises: 1) subjecting a long fatty chain diacid to an esterification reaction in order to obtain a long fatty chain di...
|
|
WO/2021/192488A1 |
The purpose of the present invention is to provide a method for producing an amide bond-containing compound with which an active acid raw material having an aromatic heterocycle to which a carbonyl group is bonded can be easily removed. ...
|
|
WO/2021/195183A1 |
The invention provides compounds that are inhibitors of the protein embryonic ectoderm development (EED), pharmaceutical compositions, their use in modulating the activity of EED, and their use in the treatment of medical disorders, such...
|
|
WO/2021/189143A1 |
There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its...
|
|
WO/2021/185304A1 |
A method for preparing a long aliphatic chain diacid derivative. The method comprises: (1) performing a cyclization reaction on long aliphatic chain diacid, the long aliphatic chain diacid having a structure as shown in formula (A); (2) ...
|
|
WO/2021/179049A1 |
The present invention relates to the treatment of disorders associated with oxidative stress including neuropathic pain and small synthetically derived compounds for treating such disorders.
|
|
WO/2021/183542A1 |
Methods for making a dolastatin, auristatin or related compounds comprising the steps of providing a universal dolastatin core of Formula (I) reacting the C-terminal carboxylic acid group with an amine (A) to form an amide bond and react...
|
|
WO/2021/183639A1 |
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are particularly useful for the treatment of itch and other dermal conditions.
|
|
WO/2021/180080A1 |
Disclosed in the present invention are a compound and a preparation method therefor, wherein the compound has a structure as shown in formula (I) and formula (II). The compound is used in the prevention or treatment of myopia-related dis...
|
|
WO/2021/177219A1 |
Provided is a catalyst which can be used for enabling a reductive amination reaction under a low-temperature low-hydrogen-pressure condition, comprises cobalt supported on an oxide, and is characterized by being produced by a method incl...
|
|
WO/2021/178841A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and comp...
|
|
WO/2021/170658A1 |
The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating ...
|
|
WO/2021/166664A1 |
Provided are: a fluorine-containing copolymer composition containing a fluorine-containing copolymer and a fluorine-containing compound having two maleimide groups; a cross-linked product of said composition; and a compound.
|
|
WO/2021/167262A1 |
The present invention relates to a composition for inhibiting toxicity of a pathogenic microorganism, a composition for prevention or treatment of pathogenic microorganism infection, a composition for control of a plant disease, each com...
|
|
WO/2021/166934A1 |
Provided is a production method suitable for the industrial production of N-{(2S,3S)-2-[(2,3'-difluorobiphenyl-3-yl)methyl]-1-(2-hydro
xy-2-methylpropanoyl)pyrrolidin-3-yl}ethane sulfonamide, N-{(2S,3S)-1-(2-hydroxy-2-methylpropanoyl)-2-...
|
|
WO/2021/165927A1 |
Nitrogen containing compounds of Formula (I), pharmaceutical compositions comprising these compounds and their use in treating hypoglycaemia is disclosed.
|
|
WO/2021/161887A1 |
[Problem] To provide a novel compound which has high absorption selectivity for the long-wavelength ultraviolet to near ultraviolet region close to a wavelength of 400 nm, exhibits high weathering resistance, and has a merocyanine skelet...
|
|
WO/2021/160139A1 |
A 9,10-dihydrophenanthrene compound and use thereof in the treatment of liver injury. Specifically, a compound of formula (I) or a compound of formula (II) is provided, which exhibits anti-inflammatory and antioxidant activities in liver...
|
|
WO/2021/163348A2 |
The present technology is directed to compounds Formulas I, II, III, and IV as well as compositions that include one or more of the compounds and methods of making the compounds. In particular, the present compounds may be used as a repl...
|
|
WO/2021/163493A1 |
The present disclosure relates to compounds that are capable of modulating calcium ion homeostasis and treating disorders related thereto. The disclosure further relates to methods of making the aforementioned compounds.
|
|
WO/2021/099079A9 |
The invention relates to new modifications of abscisic acid, to liquid compositions of abscisic acid and to their use in agrochemical applications. The modifications and compositions of the invention contain abscisic acid in the form of ...
|
|
WO/2021/157642A1 |
The present invention improves the light emission efficiency, driving voltage, and lifespan of an organic electroluminescent element using a delayed fluorescent material. A host material for a delayed fluorescent material and comprising ...
|
|
WO/2021/159015A1 |
Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formul...
|
|
WO/2021/157593A1 |
Superior durability is demonstrated by an organic light emitting element that uses a light emitting composition including both a first compound with a PBHT value greater than 0.730 and a second compound for which ES1 is smaller than for ...
|
|
WO/2021/157551A1 |
The purpose of the present invention is to provide a composition or the like which is for lithography and from which it is possible to obtain an underlying film and a film in contact with a resist layer, capable of forming a pattern with...
|
